Home › Mercks BRIDION (sugammadex) Receives FDA Approval for the Reversal of Neuromuscular Blockade Induced by Rocuronium and Vecuronium in Adults Undergoing Surgery
 

Keywords :   


Mercks BRIDION (sugammadex) Receives FDA Approval for the Reversal of Neuromuscular Blockade Induced by Rocuronium and Vecuronium in Adults Undergoing Surgery

2015-12-17 23:52:00| Merck.com - Corporate News

Dateline City: KENILWORTH, N.J. KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada, announced today that the U.S. Food and Drug Administration (FDA) has approved BRIDION (sugammadex) Injection 100 mg/mL (equivalent to 108.8 mg/mL sugammadex sodium) for the reversal of neuromuscular blockade (NMB) induced by rocuronium bromide and vecuronium bromide in adults undergoing surgery. Language: English Contact: MerckMedia Contacts:Pamela Eisele, 267-305-3558Doris Li, 908-740-1903orInvestor Contacts:Teri Loxam, 908-740-1986Justin Holko, 908-740-1879 read more

Tags: approval adults surgery induced

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
07.11Ralco acquires Sow Magic
07.11H5N1 pigs likely became infected from contact with migratory birds
07.11BioMADE Announces $26.9 Million Invested in 17 Projects
07.11Hurricane Rafael Graphics
07.11Hurricane Rafael Public Advisory Number 15A
07.11Summary for Hurricane Rafael (AT3/AL182024)
07.11Atlantic Tropical Weather Outlook
07.11Eastern North Pacific Tropical Weather Outlook
More »